Norflurazepam, also known as N-desalkylflurazepam or norfludiazepam, is a long-acting benzodiazepine metabolite widely referenced in pharmacological, toxicological, and forensic research. It is the primary active metabolite of flurazepam and several other benzodiazepines, contributing significantly to their prolonged sedative and anxiolytic effects. Due to its extended elimination half-life, norflurazepam is frequently studied in drug metabolism, impairment analysis, and analytical reference standards.
Chemically, norflurazepam belongs to the 1,4-benzodiazepine class and acts as a positive allosteric modulator of the GABA<sub>A</sub> receptor, enhancing inhibitory neurotransmission in the central nervous system. Its long persistence in biological matrices makes it a key compound in urine, blood, and plasma detection during benzodiazepine screening.
Norflurazepam has no approved standalone medical use and is typically encountered in laboratory research, analytical validation, or forensic investigations. Regulatory status varies by jurisdiction, and handling is generally restricted to licensed or research settings.
